What strikes me odd, Is the elimination criteia between the transition period of drug performance during testing in phase 3 trials and the abrupt offering by Johnson & Johnson to take control of the drug future profits ($54,000,000) deal....and the Pfizers rumors.....
In essence, the paradox here is really a riddle within a circle of powerful giants.....positioning for power.
In the endgame, of things to come to maintain an unwavering faith for the management to prevail despite the brutal facts. this duality of bi-polar thoughts.
Leaves even the sharpest investor puzzled in regards to the out future outcome results.
Maybe thats exactly how the investment bankers want it...